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Cell Line Authentication and Mycoplasma Testing Procedures 
 
ATCC ensures authenticity of LNCaP, VCaP, 22RV1, DU145, PC3 and NCI-H660 cell lines 
using short tandem repeat analysis.  Authentication of the R1-AD1 cell line was performed by 
sequence-based validation of an AR H874Y point mutation and authentication of the R1-D567 
cell line was performed by PCR-based validation of a targeted genomic deletion of AR exons 5-
7.  Authentication of LNCaP-derived sub-lines was performed by sequence-based validation of 
an AR T878A point mutation.  Aliquots of cell culture supernatants from cells in active culture 
were evaluated regularly for mycoplasma contamination using a PCR-based method as 
described 1.  All cell line experiments were performed within 2-3 months of resuscitation of 




A lentivirus expression vector encoding AR (or GFP as control) under control of a SV40 




R1-AD1 or R1-D567 cells were transfected with a plasmid encoding FLAG tagged KLF5 
(Addgene, Plasmid #40918) using electroporation as described 2. Cells were washed twice with 
1X PBS and lysed in 1 mL IP Lysis Buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% (v/v) NP-
40, 0.5% (v/v) sodium deoxycholate supplemented with Roche Complete protease inhibitor) 
post 48 h transfection. The cell lysate was transferred to a pre-chilled Dounce homogenizer on 
ice with a type B pestle and was homogenized for 10 strokes. Debris was pelleted via 
centrifugation (12,000x g, 10 min) at 4 °C and the supernatant was transferred to a fresh tube. 
Lysates of 500 µg of total protein in 1 mL was used for each reaction. Anti-FLAG antibody (5 µg, 
Sigma) or a control anti-mouse IgG (5 µg, Santa Cruz) was added to pre-cleared lysate and was 
mixed on rotator for 1 h at 4 °C. A 50 µL slurry of Protein G-agarose was added to each reaction 
and rotated overnight at 4 °C. The agarose beads were subjected to centrifuge and washed 3 
times with 1 mL IP Lysis Buffer for 5 min. The immunoprecipitated protein from each sample 
was eluted with 50 µL of 1 x Laemmli Buffer. A 10 µL sample of the eluate was used for 
Western blot.  
 
Gene Set Enrichment Analysis (GSEA) of Public Gene Expression Databases 
 
The Co-expression tool in cBioPortal 3,4 was used to download lists of genes and their 
correlations with KLF5 expression in RNA-seq data from 150 CRPC metastatic biopsies (the 
SU2C study 5) or RNA-seq data from 176 tumors from autopsy of 63 patients that died of 
metastatic prostate cancer (the FHCRC study 6) on 12/18/2017.  Co-expression lists were 
ordered by Pearson score and trimmed to the top 1000 or bottom 1000 correlated genes.  
Intersecting the top and bottom genes in the lists derived from the SU2C or FHCRC studies 
provided a set of 100 genes positively-correlated with KLF5 expression and a set of 109 genes 
negatively-correlated with KLF5 expression in both clinical CRPC datasets.  GSEA was 
performed using GSEA v3.0 (Broad Institute, 7).  Genes were ranked using the Signal2Noise 
metric and GSEA was performed against 1000 random gene set permutations.   
 
Correlation of KLF5 with AR and NEPC Scores 
 
The Plots tool in cBioPortal 3,4 was used to analyze the relationships between KLF5 mRNA 
expression (mRNA expression, FPKM capture) and Clinical Attributes of AR Score (Capture) or 
NEPC Score (Capture) in the Metastatic Prostate Adenocarcinoma (SU2C/PCF Dream Team) 
dataset 8 on 10/9/2019.   
 
Gene Sets for Determining Activity Scores 
 
All gene sets used for determining activity scores are listed in Supplementary Data 1. The cell 
cycle progression gene list and AR activity gene list have been described 6. The 37 KLF5 target 
genes were selected by the intersect of the three GSEA leading edges where the 
CRPC_KLF5_pos gene signature was tested for enrichment in RNA-seq data from R1-D567 
cells and R1-AD1 cells cultured under DHT conditions and vehicle (ethanol) conditions. These 
GSEA analyses are illustrated in Supplementary Figs. 6b & 15d. 
 
Gene Ontology Analysis 
 
We tested for enrichment of differentially expressed genes with positive fold change (log2FC > 
0) for each comparison against the Gene Ontology (GO) database 9,10 using the goana and 
topGo functions in the edgeR package. This analysis was performed for two sets of data: the full 
positive differential expression gene lists for each differential expression comparison and the 
subset of the genes in the differential expression lists annotated with KLF5/ARCommon ChIP-
seq peak associations (within +/- 50 kb).   
 
Prediction of Patient Response to Lapatinib 
 
RNA-seq data from 90 samples analyzed in the Prostate Cancer Medically Optimized Genome-
Enhanced Therapy (PROMOTE) study 11 were obtained from dbGap (phs001141.v1.p1). 
Sequence quality control metrics were calculated using FASTQC (v0.11.8) 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc). The illumina sequencing adaptors 
were removed using Trim Galore (v0.6.0) ( 
https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/ ). Next, raw RNA-Seq reads 
were mapped to the human reference genome (hg19) using TopHat (v2.0.6) 1 with bowtie1 
aligner options. Raw reads count for genes were calculated using featureCounts 2 package 
(v1.5.2) with parameter “-p” for paired-end reads and GENCODE human gene model (version 
19) as the reference gene model. The gene expression values were measured by the 
normalized value of fragments per kilobase of exon model per million fragments mapped 
(FPKM) 3 using in-house Python script. 
 
RNA-seq data from 212 samples analyzed by exome capture in the Prostate Cancer Foundation 
Stand-Up-To-Cancer East Coast Study (SU2C-EC) 5,8 were downloaded from cBioPortal 3,4 on 
1/4/2020 using the following link: http://download.cbioportal.org/prad_su2c_2019.tar.gz.  RNA-
seq data from 551 samples analyzed in The Cancer Genome Atlas Prostate Adenocarcinoma 
Study (TCGA-PRAD) 12 was downloaded from UCSC Xena 13 on 6/21/2019 using the following 
link: https://gdc.xenahubs.net/download/TCGA-PRAD/Xena_Matrices/TCGA-
PRAD.htseq_fpkm.tsv.gz.  Cancer cell line drug sensitivity data was obtained from the Cancer 
Therapeutics Response Portal Version 2 (CTRPv2) cancer cell line screen 14-16, downloaded on 
11/7/2017 using the following link: ftp://caftpd.nci.nih.gov/pub/OCG-
DCC/CTD2/Broad/CTRPv2.0_2015_ctd2_ExpandedDataset/CTRPv2.0_2015_ctd2_ExpandedD
ataset.zip and cancer cell line gene expression data was downloaded from the Cancer Cell Line 
Encyclopedia (CCLE) 17 on 11/7/2017 using the following link: 
https://data.broadinstitute.org/ccle/CCLE_RNAseq_081117.rpkm.gct.  These datasets were 
used to predict lapatinib sensitivities for the patients in each study as described 18. Briefly, a 
ridge regression was used to model measured lapatinib sensitivity in CTRPv2 cell lines using 
the gene expression data for those cell lines from CCLE. This regression model was then 
applied to RNA-seq gene expression data from PROMOTE, SU2C-EC, and TCGA-PRAD to 
predict lapatinib sensitivity in those patients. Pearson correlation coefficients were then 
calculated between predicted lapatinib sensitivities and KLF5 gene expression for each dataset. 
We also calculated Pearson correlation coefficients between predicted lapatinib sensitivities and 
a KLF5 activity score for each dataset. Analyses were performed using R version 3.6.1, RStudio 
version 1.2.5019, and the following R packages: readxl version 1.3.1, progress version 1.2.2, 











Supplementary Table 1: PCR Primer Sequences 
Primer Name Primer Sequence 
KLK3 RT-PCR Forward 5’-AGGCCTTCCCTGTACACCAA 
KLK3 RT-PCR Reverse 5’-GTCTTGGCCTGGTCATTTCC 
KLF5 RT-PCR Forward (human) 5’-ACACCAGACCGCAGCTCCA 
KLF5 RT-PCR Reverse (human) 5’-TCCATTGCTGCTGTCTGATTTGTAG 
Klf5 RT-PCR Forward (mouse) 5’-GAGGACTCATACGGGCGAGA 
Klf5 RT-PCR Reverse (mouse) 5’-CAGTTCTGGTGGCGCTTCAT 
PPP1R1B RT-PCR Forward 5’-CAGCACTAAGTGAGCCTGGG 
PPP1R1B RT-PCR Reverse 5’-CTTCCTCCTGGGAGATGCAG 
ERBB2 RT-PCR Forward 5’-ACCAAGCTCTGCTCCACACT 
ERBB2 RT-PCR Reverse 5’-ACTGGCTGCAGTTGACACAC 
FAM129B RT-PCR Forward 5’-GCCAGCACATCGCAGAAAAA 
FAM129B RT-PCR Reverse 5’-CGCATGCTGTTGAAGAGAGC 
LGALS7 RT-PCR Forward 5’-CCTTCGAGGTGCTCATCATC 
LGALS7 RT-PCR Reverse 5’-GAAGATCCTCACGGAGTCCA 
ACTB RT-PCR Forward 5’-CTCTTCCAGCCTTCCTTCCT 
ACTB RT-PCR Reverse 5’-AGCACTGTGTTGGCGTACAG 
Gapdh RT-PCR Forward (mouse) 5’- CAATGAATACGGCTACAGCAAC 






















Supplementary Figure 1.  KLF5 expression in LNCaP-95 cells.  a KLF5 mRNA measured 
using quantitative RT-PCR in LNCaP and LNCaP-95 cells Data represent 3 independent 
biological replicates performed in technical triplicate (n=9).  Individual data points are shown 
along with mean +/- 95% CI.  b KLF5 protein measured by western blot in LNCaP and LNCaP-
















Supplementary Figure 2.  Androgen regulation of KLF5.  a KLF5 and AR protein measured 
by western blot in PC-3 cells infected with lentivirus encoding AR (or GFP as control), treated 8 
or 24 hours with 1 nM DHT. One additional replicate experiment was performed that yielded a 
comparable result. b KLF5 and AR protein measured in DU145 cells infected and treated as in 
a. One additional replicate experiment was performed that yielded a comparable result. c KLK3 
(encoding PSA) mRNA measured by RT-PCR in LNCaP cells treated with 1 nM DHT. n = 9, 
mean +/- 95% CI from 3 biological replicates in technical triplicate. d KLF5 and AR protein 
measured by western blot in LNCaP cells transfected with AR-targeted siRNA (AR1 and AR2) 
or control siRNA. One additional replicate experiment was performed that yielded a comparable 
result. e KLF5 protein measured by western blot in LNCaP cells treated with 0.1-10 nM DHT or 
R1881 (or ethanol as vehicle control) for 8 h or 24 h. One additional replicate experiment was 













Supplementary Figure 3. H3K27ac and H3K4me1 ChIP-seq data at KLF5, KLK2/3, and 
housekeeping gene loci. a-c H3K27ac ChIP-seq data from LNCaP, VCaP, and PC-3 cells at 
genomic loci for housekeeping controls GAPDH (encodes glyceraldehyde 3-phosphate 
dehydrogenase), ACTB (encodes beta-actin), and TUBA1A-C (encode tubulin alpha-1A, -1B, 
and -1C chains). d-h H3K4me1 ChIP-seq data from LNCaP, VCaP, and PC-3 cells at genomic 
loci for KLF5, KLK2/3, GAPDH, ACTB, and TUBA1A-C. i-k H3K27ac ChIP-seq data from 4 







Supplementary Figure 4.  Effects of KLF5 expression on cell growth in 2-dimensional 
(2D) growth assays.  a R1-AD1 cells infected with lentivirus encoding shRNAs targeting KLF5 
or control shRNA were seeded on tissue culture plates in medium supplemented with 10% 
charcoal-stripped (steroid depleted) medium containing 0.1% v/v ethanol.  Cells were subjected 
to 2D growth assays by fixing and crystal violet staining at indicated time points.  b 2D growth 
assays as in a with medium containing 1 nM dihydrotestosterone (DHT).  c 2D growth assays 
as in a with LNCaP cells infected with empty lentivirus or lentivirus encoding KLF5.  d 2D growth 
assays as in c with medium containing 1 nM DHT.  Data represent 9 independent biological 
replicates (n=9).  Individual data points are shown along with mean +/- 95% CI.  P-values were 























Supplementary Figure 5.  Co-Immunoprecipitation of AR and FLAG-KLF5.  R1-AD1 cells 
expressing FLAG-KLF5 were lysed and subjected to immunoprecipitation with anti-FLAG 
antibodies or IgG control.  Immunoprecipitates were analyzed by western blot using antibodies 
specific for AR and KLF5. The input lane represents 5% of the lysate. Two additional replicate 


















Supplementary Figure 6.  Gene set enrichment analysis of KLF5-correlated gene sets 
from clinical CRPC specimens in RNA-seq data from R1-AD1 KLF5 knock-down cells.   
a The 100-gene CRPC_KLF5_pos gene set was derived from the intersection of the top 1000 
genes positively correlated with KLF5 expression in the AACR-PCF Stand-Up-To-Cancer study 
of CRPC biopsies (SU2C) or Fred Hutchinson Cancer Research Center study of CRPC 
autopsies (FHCRC).  The 109-gene CRPC_KLF5_neg gene set was derived using the same 
intersection strategy, but with the bottom 1000 genes that correlated with KLF5 expression.   
b Gene set enrichment analysis was used to test enrichment of the CRPC_KLF5_pos and 
CRPC_KLF5_neg gene sets in RNA-seq data from R1-AD1 cells cultured in the presence of 
dihydrotestosterone (DHT) or vehicle control (ethanol, ETH), ordered by differential expression 




Supplementary Figure 7.  KLF5- and androgen-regulated genes in R1-AD1 cells.   
a Differentially-expressed genes in R1-AD1 cells infected with lentivirus encoding KLF5 shRNA 
(shKLF5) vs. control shRNA (shCTRL).  Data reflect RNA-seq data collected from 3 
independent biological replicate experiments with cells that were infected with shCTRL or 2 
independent shKLF5 constructs.  Cells in a were cultured in medium supplemented with 10% 
charcoal-stripped (steroid-depleted) serum (10% CSS) plus vehicle control (ethanol, ETOH).   
b Differentially expressed genes in R1-AD1 cells infected and analyzed exactly as in a with cells 
cultured in 10% CSS medium supplemented with 1 nM dihydrotestosterone (DHT).   
c Differentially-expressed genes in shCTRL-infected R1-AD1 cells cultured in medium 
containing 10% CSS medium supplemented with ETOH vs. 1 nM DHT.  d Differentially-
expressed genes in shKLF5-infected R1-AD1 cells cultured +/- DHT as in c.  Sizes of dots in 
plots reflect the log2 of counts per million (CPM) measured for that gene.  e Heatmap of RNA-





Supplementary Figure 8.  GSEA Oncogenic Signatures and Fisher’s exact test 
contingency table.  a Normalized enrichment scores for all 189 MSigDB Oncogenic Signatures 
derived from gene set enrichment analysis (GSEA) using R1-AD1 gene expression data 
reflecting KLF5 activity (differential expression under shCTRL vs. shKLF5). b GSEA-derived 
normalized enrichment scores as in a using R1-AD1 gene expression data reflecting AR activity 
(differential expression in ETH vs. DHT). Oncogenic Signatures are colored blue or red based 
on whether they were positively- or negatively-enriched in a with FDR<0.01. c Contingency 
table indicating the number of mSigDB oncogenic signatures that were DHT enriched and 
shCTRL enriched, DHT enriched and shKLF5 enriched, ETH enriched and shCTRL enriched, or 
ETH enriched and shKLF5 enriched. P-value is from 2-sided Fisher’s exact test. d GSEA testing 
enrichment of luminal, basal, and neuroendocrine (NE) gene signatures in R1-AD1 data 
reflecting active KLF5 (shCTRL vs. shKLF5) or active AR (DHT vs ETH) as indicated. FDR-
















Supplementary Figure 9.  Correlation of KLF5 expression with AR and NEPC activity 
scores.   a Plot of KLF5 mRNA expression in fragments per kb per million mapped reads 
(FPKM) vs. an AR activity score.  Plots were developed using data from a set of 209 CRPC 
tissues subjected to RNA-seq using hybrid capture. P-values are from 2-sided Spearman rank 
correlation and Pearson correlation tests as indicated. b Plot of KLF5 mRNA expression (in 
FPKM) vs. a neuroendocrine prostate cancer (NEPC) score developed from the same samples 

















Supplementary Figure 10.  KLF5 expression and target genes in clinical neuroendocrine 
CRPC (NEPC). a Immunohistochemistry (IHC) staining of NEPC patient derived xenograft 
(PDX) tissues with a KLF5 antibody. Images represent one TMA spot out of nine stained for 
KLF5 in each tissue, with similar results. b Hematoxylin and eosin (H&E, left) and IHC (right) 
staining of a NEPC metastatic biopsy (liver) with a KLF5 antibody. Images represent one KLF5 
IHC stain performed on this tissue biopsy.  c Enrichment of the 
AD1_DHT_shCON_vs_shKLF5_UP get set in gene expression data rank-ordered based on 
differential expression in clinical NEPC vs. CRPC tissues. Unadjusted and FDR-corrected P-
values were provided in GSEA output. d Enrichment of the AD1_DHT_shCON_vs_shKLF5_UP 
get set in gene expression data rank-ordered based on differential expression in clinical NEPC 
vs. primary prostate cancer (PCa) tissues. Unadjusted and FDR-corrected P-values were 
provided in GSEA output.  e Enrichment of the AD1_ETH_shCON_vs_shKLF5_UP get set in 
gene expression data rank-ordered based on differential expression in clinical NEPC vs. CRPC 
tissues. Unadjusted and FDR-corrected P-values were provided in GSEA output.  f Enrichment 
of the AD1_ETH_shCON_vs_shKLF5_UP get set in gene expression data rank-ordered based 
on differential expression in clinical NEPC vs. primary prostate cancer (PCa) tissues.  





Supplementary Figure 11.  Motif enrichment at AR and KLF5 peaks.  a Motifs enriched at 
2,412 KLF5/AR common peaks are plotted based on motif enrichment score determined by 
MEME-ChIP.  Motifs with outlier enrichment score are indicated. b Motifs enriched at 20,985 










Supplementary Figure 12.  Gene Ontology (GO) analysis of KLF5 target genes.  a GO 
terms enriched for genes that display differential expression in RNA-seq data from R1-AD1 cells 
infected with lentivirus harboring shRNA targeted to KLF5 (shKLF5) vs. control shRNA 
(shCTRL). P-values are from output of the goana and topGo functions in edgeR.  b GO terms 
enriched for genes located within +/- 50 kb from a shared KLF5/AR common peak and 
displaying differential expression in RNA-seq data from R1-AD1 cells infected with lentivirus 
harboring shRNA targeted to KLF5 (shKLF5) vs. control shRNA (shCTRL).  GO terms 
associated with ERBB/epidermal growth factor receptor signaling pathways are highlighted in 












Supplementary Figure 13.  Validation of KLF5 Target Genes.  a mRNA levels of indicated 
targets were measured by RT-PCR in R1-AD1 cells transfected with KLF5-targeted siRNAs 
(siK1 and siK2) or control siRNA (siC) and maintained in androgen-depleted medium. Data are 
presented as mean +/- 95% CI with individual data points shown for 4 biological replicate 
experiments each performed in technical duplicate (n=8). b,c Cytokeratin-5 (CK5), Cytokeratin-
8/18 (CK8/18), and KLF5 protein measured by western blot in LNCaP-16D and LNCaP-42D 
cells transfected and treated as in a. One additional replicate experiment was performed in each 
of LNCaP-16D and LNCaP-42D that yielded comparable results. d mRNA levels of indicated 
targets were measured by RT-PCR in PC-3 cells transfected and treated as in a. Data are 
presented as mean +/- 95% CI with individual data points shown for 4 biological replicate 


















Supplementary Figure 14.  KLF5 interaction with AR variant (AR-V) protein ARv567es.  a 
KLF5 peptides identified in AR immunoprecipitates generated using rapid immunoprecipitation 
and mass spectrometry of endogenous proteins (RIME).  b R1-D567 cells were transfected with 
a vector encoding FLAG-tagged KLF5.  Proteins immunoprecipitated (IP) with FLAG antibody or 
control IgG were analyzed by immunoblot (IB) with antibodies specific for the AR N-terminal 














Supplementary Figure 15.  Effects of KLF5 expression on R1-D567 cell growth in 2-
dimensional (2D) growth assays.  R1-D567 cells infected with lentivirus encoding shRNAs 
targeting KLF5 or control shRNA were seeded on tissue culture plates in medium supplemented 
with 10% charcoal-stripped (steroid depleted) medium.  Cells were subjected to 2D growth 
assays by fixing and crystal violet staining at indicated time points.  Data represent 9 
independent biological replicates (n=9).  Individual data points are shown along with mean +/- 
















Supplementary Figure 16.  Identification of KLF5 target genes in R1-D567 cells using 
RNA-seq.  a Schematic of workflow for infection of R1-D567 cells with lentivirus encoding 
control shRNA (shCTRL) or two independent shRNAs targeting KLF5 (shKLF5).  b Western blot 
of lysates from cells infected as in a.  Blots were probed with antibodies specific for KLF5 or 
ERK2 as loading control.  Two additional replicate experiments were performed that yielded 
comparable results. c Volcano plots of differentially-expressed genes in R1-D567 cells infected 
with lentivirus and analyzed by RNA-seq as in a.  d Gene set enrichment analysis of KLF5-
correlated clinical gene sets (CRPC_KLF5_pos and CRPC_KLF5_neg) in RNA-seq data from 
























Supplementary Figure 17.  Validation of KLF5 Target Genes in R1-D567 Cells.  R1-D567 
cells were transiently transfected with KLF5-targeted siRNAs (siK1 and siK2) or control siRNA 
(siC) and maintained in androgen-replete medium. mRNA expression levels of KLF5, ERBB2, 
LGALS7, PPP1R1B, and FAM129B were analyzed by RT-PCR.  Data are presented as mean 
+/- 95% CI with individual data points shown for 4 biological replicate experiments each 





Supplementary Figure 18.  Correlations of KLF5 Expression and Activity with Predicted 
Lapatinib Sensitivities.  a Relative expression of 37 genes in the KLF5 activity score in NEPC 
patient-derived organoids (OWCM155 and OWCM154) and CRPC adenocarcinoma patient-
derived organoids (MSK-PCa3). Bounds of boxes are lower/upper quartiles with median as a 
bold horizontal line and mean as a “+” sign, whiskers show range from minima to maxima; dots 
are the Z-score for each of the 37 genes in the KLF5 activity score. P-values are unadjusted 
from two-sided unpaired t-tests. b Relative expression of 16 housekeeping genes, with boxplots 
and t-tests as defined in a. c Z-scores of individual gene expression in indicated samples. d, e 
Ridge regression models trained on high-throughput cancer cell line drug screens were used to 
predict lapatinib sensitivity in prostate tumors from RNA-seq data generated by The Cancer 
Genome Atlas Prostate Adenocarcinoma Study (TCGA-PRAD).  The predicted lapatinib 
sensitivity score was plotted vs. a KLF5 expression in Log2 FPKM (fragments per kilobase per 
million fragments mapped) or b KLF5 activity determined from summative z-scores of 37 KLF5 















Supplementary Figure 19.  Sensitivity of R1-AD1 and R1-D567 cells to lapatinib.  a R1-
AD1 and b R1-D567 cells were cultured in androgen-replete growth medium supplemented with 
indicated concentrations of lapatinib.  Cells were subjected to 2-dimensional growth assays by 
fixing and crystal violet staining at start of treatment (day 0) and after 6 days treatment.  Light 
gray lines represent growth data from individual biological replicate experiments (n=9) and dark 
lines represent the mean +/- 95% CI.  Drug concentrations that resulted in 50% growth inhibition 
(IC50) were calculated from each biological replicate (n=9).  The listed IC50 represents the 




Supplementary Figure 20.  Full western blot images for Figures 1&2   
 
Supplementary Figure 21. Full western blot images for Figures 3-6 
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